Free Trial

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare logo
$328.28 -4.72 (-1.42%)
(As of 01:10 PM ET)

HCA Healthcare - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
14

Based on 19 Wall Street analysts who have issued ratings for HCA Healthcare in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 5 have given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for HCA.

Consensus Price Target

$385.00
17.28% Upside
According to the 19 analysts' twelve-month price targets for HCA Healthcare, the average price target is $385.00. The highest price target for HCA is $440.00, while the lowest price target for HCA is $271.00. The average price target represents a forecasted upside of 17.28% from the current price of $328.28.
Get the Latest News and Ratings for HCA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for HCA Healthcare and its competitors.

Sign Up

HCA Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$385.00$367.15$356.17$296.59
Forecasted Upside17.28% Upside-10.05% Downside-8.39% Downside17.22% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

HCA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HCA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HCA Healthcare Stock vs. The Competition

TypeHCA HealthcareMedical CompaniesS&P 500
Consensus Rating Score
2.84
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside15.62% Upside26,931.47% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent HCA News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/8/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$396.00 ➝ $392.00+11.12%
11/6/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetEqual Weight ➝ Equal Weight$395.00 ➝ $400.00+14.58%
10/28/2024TD Cowen
4 of 5 stars
 Lower TargetBuy ➝ Buy$450.00 ➝ $440.00+22.05%
10/28/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$390.00 ➝ $400.00+10.22%
10/28/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Gillmor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$475.00 ➝ $420.00+15.73%
10/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$392.00 ➝ $392.00-3.18%
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

9/3/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight$427.00+7.94%
8/29/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Lake
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/23/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$378.00 ➝ $405.00+5.09%
8/19/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$390.00 ➝ $430.00+15.30%
8/14/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$405.00 ➝ $438.00+18.74%
7/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$367.00 ➝ $396.00+16.32%
6/28/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$359.00 ➝ $375.00+14.85%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$327.00 ➝ $332.00-0.86%
5/30/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$396.00+21.88%
1/31/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$300.00 ➝ $330.00+9.45%
1/4/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$277.00 ➝ $301.00+9.85%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$271.00+5.23%
11/10/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$280.00+20.26%
10/25/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$325.00 ➝ $275.00+21.19%
10/25/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$324.00 ➝ $279.00+22.87%
7/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$311.00 ➝ $316.00+14.31%
6/28/20231-800-FLOWERS.COM
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/28/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/10/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $310.00+13.12%
4/24/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$325.00 ➝ $350.00+23.24%
4/24/2023Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$285.00 ➝ $320.00+13.79%
4/24/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$294.00 ➝ $323.00+14.86%
1/30/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$238.00 ➝ $292.00+14.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:26 PM ET.


HCA Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for HCA Healthcare is $385.00, with a high forecast of $440.00 and a low forecast of $271.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HCA Healthcare in the last year. There are currently 5 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HCA shares.

According to analysts, HCA Healthcare's stock has a predicted upside of 17.28% based on their 12-month stock forecasts.

Over the previous 90 days, HCA Healthcare's stock had 2 upgrades by analysts.

HCA Healthcare has been rated by research analysts at Barclays, Cantor Fitzgerald, KeyCorp, Morgan Stanley, Oppenheimer, Royal Bank of Canada, TD Cowen, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like HCA Healthcare more than other "medical" companies. The consensus rating score for HCA Healthcare is 2.84 while the average consensus rating score for "medical" companies is 2.80. Learn more on how HCA compares to other companies.


This page (NYSE:HCA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners